G1GLP1 Note Applies to All countries

HomeNew drugsRetatrutide

New drugAll countries · Checked

Retatrutide FDA Approval: Timeline and Expected Release Date

Retatrutide is not approved by the FDA or any other regulator as of November 20, 2026. Eli Lilly plans to file its US application in the first quarter of 2027 and has not announced a release date.

Retatrutide approval status

Not filed yet, so no approval and no release date.

Stage todayPhase 3 results out, not filed

Next stepUS filing planned for Q1 2027

Release dateNone announced

Based on Lilly's own announcements. This page is updated when a filing or a decision is announced.

Want to know what approved weight loss medicines cost today?

Compare GLP-1 medicine prices by country

Lilly's approved weight loss injection is covered in Zepbound approval dates.

Approved?Release dateTimelineResultsDiabetes resultsSide effectsDosePriceWhat it isFAQ

Is retatrutide FDA approved?

No. The FDA has not approved retatrutide, and Lilly has not filed for approval yet. Lilly calls it an investigational medicine.

Lilly says retatrutide is legally available only to people in its clinical trials.

A product sold online under the name retatrutide is not an approved medicine.

Retatrutide release date

There is no release date. A filing has to come first, and then a regulator has to review it.

On August 5, 2026, Lilly said in its second-quarter results that it plans to submit a Biologics License Application to the FDA in the first quarter of 2027.

In its July 23, 2026 announcement, Lilly said it is finishing the manufacturing data a filing requires and will submit after that.

So the first quarter of 2027 is the earliest filing date, and approval and launch come after it.

Retatrutide approval timeline

1Phase 3 resultsDoneTRIUMPH-1 reported on May 21, 2026, TRIUMPH-2 and TRIUMPH-3 in July 2026.

2Manufacturing dataIn progressLilly says it is finishing this package before it files.

3US filingPlanned for Q1 2027Lilly submits its Biologics License Application to the FDA.

4FDA review and decisionNo date yetA decision date is set only after the filing.

5LaunchNo date yetThe maker sets this after an approval.

Lilly has not given filing dates for other countries. It says the data package now supports submissions worldwide.

That leaves the UK, Canada, Australia and India without a date as well, because a regulator in each country decides only after a filing there.

Retatrutide phase 3 results

The biggest trial is TRIUMPH-1. It randomized 2,339 adults with obesity, or overweight plus a related condition and no diabetes, to retatrutide 4 mg, 9 mg, 12 mg or placebo once a week for 80 weeks.

4 mg−19.0%9 mg−25.9%12 mg−28.3%

Placebo lost 2.2%. These averages follow people who stayed on treatment.

Counting everyone assigned to a dose, including those who stopped, the averages were −17.6% on 4 mg, −23.7% on 9 mg and −25.0% on 12 mg, against −3.9% on placebo.

On 12 mg, 45.3% lost at least 30% of their body weight and 65.3% ended with a BMI under 30. You can check your own number with the BMI calculator.

A pre-planned extension followed 532 people with a BMI of 35 or more. Those assigned 12 mg lost 30.3% on average by 104 weeks, with doses allowed up to the highest they could tolerate, 9 mg or 12 mg.

These are trial averages, not a promise for any one person.

Retatrutide results with type 2 diabetes

TRIUMPH-2 followed adults with type 2 diabetes and obesity or overweight for 80 weeks.

4 mg−12.7%9 mg−19.1%12 mg−20.8%

Placebo lost 4.0%. HbA1c fell by 1.4 to 1.6 points on retatrutide from a starting level of 7.7%, against 0.2 on placebo.

Weight loss was smaller than in TRIUMPH-1, so do not compare the two sets of numbers directly.

TRIUMPH-3 enrolled adults with severe obesity and established heart disease. At 80 weeks they lost 21.6% on 9 mg and 22.6% on 12 mg, against 3.2% on placebo.

That trial was built to measure weight, so its heart event counts are not proof that the drug protects the heart.

Retatrutide side effects

The most common side effects are stomach and gut problems. On 12 mg in TRIUMPH-1, 42.4% had nausea, 32.0% diarrhea, 26.1% constipation and 25.3% vomiting.

On placebo the rates were 14.8%, 13.5%, 10.9% and 4.8%.

Dysesthesia, an odd skin feeling such as tingling or burning, hit 12.5% on 12 mg against 0.9% on placebo. Most cases were mild to moderate, and the majority resolved during treatment.

Stopping because of side effects happened in 4.1% on 4 mg, 6.9% on 9 mg and 11.3% on 12 mg, against 4.9% on placebo.

There is no approved label yet, so there is no official side effect table or boxed warning.

Retatrutide dose

There is no approved dose. In TRIUMPH-1 everyone on retatrutide started at 2 mg once a week and stepped up every four weeks.

The 4 mg group took one step at 2 mg, the 9 mg group stepped through 2, 4 and 6 mg, and the 12 mg group through 2, 4, 6 and 9 mg.

That schedule is a research plan, not dosing guidance.

For a dose chart of an approved Lilly injection, see the Zepbound dosing chart.

Retatrutide price

There is no price because the medicine is not for sale, and Lilly has announced none.

You can compare approved medicines in GLP-1 price by country or estimate your own monthly bill with the GLP-1 cost calculator.

What is retatrutide?

Retatrutide is a once-weekly injection that switches on three receptors: GIP, GLP-1 and glucagon. Eli Lilly is developing it.

Zepbound's tirzepatide acts on GIP and GLP-1. Retatrutide adds glucagon to that pair.

Lilly is also studying it in type 2 diabetes, knee osteoarthritis pain, moderate-to-severe sleep apnea, chronic low back pain, heart and kidney outcomes, and fatty liver disease.

Other medicines in late trials include survodutide and CagriSema, and the pill that is already approved is Foundayo.

Retatrutide FAQ

Is retatrutide FDA approved?

No. Lilly has not filed for approval yet.

When will retatrutide be released?

No date is set. The US filing is planned for Q1 2027, and a launch can only follow an approval.

Can I get retatrutide in the UK, Canada or Australia?

No. Lilly says it is legally available only to people in its clinical trials.

Does retatrutide work better than Zepbound?

No head-to-head result with Zepbound has been announced, so nobody knows. Each trial had different people and lengths.

How is retatrutide taken?

In the trials it was a once-weekly injection.

How many phase 3 trials of retatrutide have been positive?

Lilly reports five positive phase 3 studies as of July 2026.

Is there a trial of retatrutide against semaglutide?

Yes. TRANSCEND-T2D-2 compares the two in adults with type 2 diabetes, with about 1,250 people planned. Its registry entry shows the main data collection ended on August 27, 2026, and results are not announced.

Keep reading

New weight loss drugs 2026

Tirzepatide FDA approval dates

Survodutide trial results and timeline

CagriSema trial results and FDA decision

GLP-1 price by country

GLP-1 drugs explained

This page follows Lilly's announcements and the trial registry, and is updated when a filing or a decision is announced. See how we check our pages.

Update log

: First published.

Sources

Eli Lilly and Company, TRIUMPH-1 topline results, May 21, 2026.

Eli Lilly and Company, TRIUMPH-1 and TRANSCEND-T2D-1 at ADA 2026, June 6, 2026.

Eli Lilly and Company, TRIUMPH-2 and TRIUMPH-3 topline results, July 23, 2026.

Eli Lilly and Company, Second-quarter 2026 financial results, August 5, 2026.

ClinicalTrials.gov, NCT06260722 TRANSCEND-T2D-2.

GLP1 Note is an independent information site. Which medicine suits you is for your prescriber to decide.